Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Spinal Muscular Atrophy Type I
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Itvisma
Itvisma is indicated for the treatment of 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene in patients 2 years of age and older.
View on EMAZolgensma
Zolgensma is indicated for the treatment of: patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene.
Multiple Sclerosis
Solid Tumors
Influenza
Chronic Obstructive Pulmonary Disease
Swine-Origin Influenza A H1N1 Virus